Table 1.
Correlation Between Clinicopathogical Features and Lin28B Expression in 190 Breast Cancer Cases
Lin28B expression | |||||||
---|---|---|---|---|---|---|---|
Clinicopathological features | na(%) | Negative (%) | Positive (%) | χ2 | pb | r | pc |
All cases | 190 (100) | 107 (56.3) | 83 (43.7) | ||||
Age | 0.021 | 0.884 | |||||
≤46.5 | 95 (50.0) | 54 (28.4) | 41 (21.6) | ||||
>46.5 | 95 (50.0) | 53 (27.9) | 42 (22.1) | ||||
Menopausal status | 0.229 | 0.632 | |||||
Premenopausal | 120 (63.2) | 66 (34.7) | 54 (28.4) | ||||
Postmenopausald | 70 (36.8) | 41 (21.6) | 29 (15.3) | ||||
Tumor size (cm) | 4.729 | 0.094 | |||||
<2 | 53 (27.9) | 31 (16.3) | 22 (11.6) | ||||
2–5 | 123 (64.7) | 72 (37.9) | 51 (26.8) | ||||
>5 | 14 (7.4) | 4 (2.1) | 10 (5.3) | ||||
Histological differentiation | 13.790 | 0.001 | 0.216 | 0.003 | |||
Well | 61 (32.1) | 39 (20.5) | 22 (11.6) | ||||
Moderate | 81 (42.6) | 52 (27.4) | 29 (15.3) | ||||
Poor | 48 (25.3) | 16 (8.4) | 32 (16.8) | ||||
TNM staging | 9.213 | 0.002 | 0.220 | 0.002 | |||
I–II | 97 (51.1) | 65 (34.2) | 32 (16.8) | ||||
III–IV | 93 (48.9) | 42 (22.1) | 51 (26.8) | ||||
Metastatic lymph nodes | 30.996 | <0.0001 | 0.359 | <0.0001 | |||
0 | 72 (37.9) | 59 (31.1) | 13 (6.8) | ||||
1–3 | 45 (23.7) | 18 (9.5) | 27 (14.2) | ||||
≥4 | 73 (38.4) | 30 (15.8) | 43 (22.6) | ||||
ER | 0.160 | 0.899 | |||||
Negative | 86 (45.3) | 48 (25.3) | 38 (20.0) | ||||
Positive | 104 (54.7) | 59 (31.1) | 45 (23.7) | ||||
PR | 2.307 | 0.129 | |||||
Negative | 92 (48.4) | 57 (30.0) | 35 (18.4) | ||||
Positive | 98 (51.6) | 50 (26.3) | 48 (25.3) | ||||
Her-2 | 1.264 | 0.261 | |||||
Negative | 147 (77.4) | 86 (45.3) | 61 (32.1) | ||||
Positive | 43 (22.6) | 21 (11.1) | 22 (11.6) | ||||
Ki67 | 13.268 | <0.0001 | 0.037 | 0.677 | |||
Negative | 76 (40.0) | 55 (28.9) | 21 (11.1) | ||||
Positive | 92 (60.0) | 52 (27.4) | 62 (32.6) | ||||
Subtype | 20.450 | <0.0001 | |||||
Luminal A | 52 (27.4) | 41 (21.6) | 11 (5.8) | ||||
Luminal B | 59 (31.1) | 22 (11.6) | 37 (19.5) | ||||
Her-2 overexpression | 29 (15.3) | 14 (12.8) | 15 (7.9) | ||||
Basal like | 50 (26.3) | 30 (15.8) | 20 (10.5) |
Number of cases in each group.
p for χ2 test.
p for Spearman rank correlation.
Postmenopausal status for natural menopause.
ER, estrogen receptor; PR, progesterone receptor; TNM, tumors, lymph nodes, and metastases.